AGEN
Agenus Inc.
AGEN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over AGEN overall, supported by stronger fundamentals and lower modeled downside.
AGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
AGEN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.1x | $1.52 | -78% |
| Fair | 3.1x | $2.20 | -68% |
| Current | 9.7x | $6.87 | — |
| Expensive | 15x | $10.89 | +58% |
Historical ranges are pointers, not guarantees.
AGEN's PE is 9.7x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
AGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect AGEN's earnings and revenue to decline, though with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.71 | +$2.75 |
| Q2 2026 | $2.63 | +$9.69 |
| Q1 2026 | $1.64 | +$10.22 |
| Q4 2025 | -$0.41 | +$10.18 |
| Q3 2022 | -$14.52 | -$12.16 |
| Q2 2022 | $3.34 | +$25.32 |
| Q1 2022 | -$0.59 | +$19.63 |
| Q4 2021 | -$2.16 | +$18.84 |
AGEN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $31.5M | +4.1% |
| Q2 2026 | $34.5M | +34% |
| Q1 2026 | $33.7M | +40% |
| Q4 2025 | $34.2M | +27% |
| Q3 2025 | $30.2M | +20% |
| Q2 2025 | $25.7M | +9.3% |
| Q1 2025 | $24.1M | -14% |
| Q4 2024 | $26.8M | -68% |
AGEN's revenue has grown year over year for six quarters in a row: $31M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +51 points |
| Q2 2026 | 33% | +98 points |
| Q1 2026 | 45% | +100 points |
| Q4 2025 | 42% | +139 points |
| Q3 2025 | -15% | +110 points |
| Q2 2025 | -65% | +63 points |
| Q1 2025 | -55% | +62 points |
| Q4 2024 | -96% | -92 points |
AGEN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AGEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -$5.4M |
| Q2 2026 | -$31.2M | -$11M |
| Q1 2026 | -$36M | -$10.3M |
| Q4 2025 | -$16.6M | +$12.1M |
| Q3 2025 | -$14.7M | +$38.6M |
| Q2 2025 | -$20.2M | +$18.4M |
| Q1 2025 | -$25.6M | +$12.6M |
| Q4 2024 | -$28.7M | +$11.9M |
AGEN has burned cash in almost every quarter: −$104M over the past year, against −$89M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +101% | +41.9M shares |
| 1 year | +196% | +55.2M shares |
| 3 years | +795% | +74M shares |
AGEN has 83M diluted shares, up 196% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $42,000 |
| Q3 2023 | $328,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over AGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.3x | Net Cash |
| Q2 2022 | -3.6x | Net Cash |
| Q1 2022 | -6.1x | Net Cash |
| Q4 2021 | -8.6x | Net Cash |
| Q3 2021 | -3.7x | Net Cash |
AGEN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AGEN on leverage, with a lower net debt burden relative to earnings.
AGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 22.9 | Neutral |
AGEN's weekly RSI is 54 (neutral) and its Stochastic is 23 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AGEN PE vs Healthcare Sector
| Metric | AGEN | Sector median | Relative |
|---|---|---|---|
| PE | 9.7x | 26x | 62% below |
| PE % | 64 | 29 | 35 pts above |
AGEN has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.22 | 4.8% below |
| 20 week MA | $6.81 | 0.9% above |
| 50 week MA | $4.78 | 44% above |
| 100 week MA | $4.30 | 60% above |
| 200 week MA | $11.7 | 41% below |
AGEN's trend is mixed: it's above three of its five weekly moving averages, and 41% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AGEN on trend strength, trading above more of its moving averages.
AGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $82.8 | $67.7 | -18% |
| 2021 | $67.7 | $71.6 | +5.8% |
| 2022 | $71.6 | $49.1 | -32% |
| 2023 | $49.1 | $16.6 | -66% |
| 2024 | $16.6 | $2.75 | -83% |
| 2025 | $2.75 | $3.31 | +20% |
| 2026 YTD | $3.31 | $6.87 | +108% |
AGEN is up 108% so far in 2026, after finishing lower in four of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AGEN on returns for 2026, with the stronger performance.